French consensus: Treatment of newly diagnosed restless legs syndrome.

N Limousin, M Flamand, C Schröder, C Charley Monaca

Review Revue neurologique 2018 13 인용

<\/script>\n

`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D30054010'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Abstract

Treatment of restless legs syndrome (RLS) must only be considered after a definite positive diagnosis. The RLS phenotype must be characterised precisely, iron deficiency always tested for, and aggravating factors eliminated when possible. Medical treatment is considered for severe or very severe forms and based on dopaminergic agonists, α2δ-1 ligands and/or opioids. First line treatment will be a low-dose monotherapy and the choice of treatment depends on the results of the clinical examination and investigations.

요약

Treatment of restless legs syndrome (RLS) must only be considered after a definite positive diagnosis, the RLS phenotype must be characterised precisely, iron deficiency always tested for, and aggravating factors eliminated when possible.

Used In Evidence Reviews

A 철분 관련 하지불안증후군

French consensus: Treatment of newly diagnosed restless legs syndrome.

Embed This Widget

Abstract

요약

Used In Evidence Reviews

Similar Papers

Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).

Restless legs syndrome and pregnancy.

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice.

Restless legs syndrome: pathophysiology, clinical presentation and management.

Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).

Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.